{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-014660","form_type":"8-K","ticker":"GALT","cik":"0001133416","company_name":"GALECTIN THERAPEUTICS INC","filed_at":"2023-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.948489+00:00","generated_at":"2026-06-17T08:54:41.867202+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Galectin Therapeutics reports 2022 net loss of $38.9M; NAVIGATE trial on track","bullets":["Net loss $38.9M ($0.65/share) vs $30.7M ($0.52) in 2021.","R&D expenses $31.7M, up from $23.8M, driven by NAVIGATE trial costs.","Cash $18.6M; $50M credit line available; expects funding through Dec 2024.","NAVIGATE trial randomized 357 patients; DSMB positive; interim results Q4 2024.","Evaluating Phase 2 trial of belapectin + Keytruda for head and neck cancers."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-014660","json":"https://secwatch.observer/filing/0001140361-23-014660.json","markdown":"https://secwatch.observer/filing/0001140361-23-014660.md","text":"https://secwatch.observer/filing/0001140361-23-014660.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133416/000114036123014660/0001140361-23-014660-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133416/000114036123014660/brhc10050428_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T08:54:41.867202+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f204fb4921cd93be2c14e42cd6c5bfe38a577472","claim":"GALECTIN THERAPEUTICS INC reported the year ended December 31, 2022 results: net income $38.9 million, EPS ($0.65) per share.","evidence_excerpt":"For the year ended December 31, 2022, the Company reported a net loss applicable to common stockholders of $38.9 million, or ($0.65) per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133416/000114036123014660/0001140361-23-014660-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Net income","value":"$38.9 million"},{"label":"EPS","value":"($0.65) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}